Ligand Pharmaceuticals Inc. | Stephens

Who We Are

What We Do

We provide investment banking, research, sales and trading, asset and wealth management, public finance, insurance, private capital, and family office services.

About Us

We are a family-owned financial services firm that values client relationships, long-term stability, and supporting the communities where we live and work.

The Stephens Story

The idea of family defines our culture, because each of us knows that our reputation is on the line as if our own name was on the door.


Our reputation as a leading independent financial services firm is built on the stability of our longstanding and highly experienced senior executives.

Impact Initiatives

We are committed to corporate philanthropy; economic and financial literacy advocacy; and diversity, equity, and inclusion initiatives.

Our Brand Ambassadors

Stephens is proud to sponsor the PGA TOUR, LPGA Tour, and PGA TOUR Champions careers, as well as applaud the philanthropic endeavors, of our Brand Ambassadors.

Making Connections

We host many highly informative meetings each year with clients, industry decision makers, and thought leaders across the U.S. and in Europe.

Back to transactions

Ligand Pharmaceuticals Inc.

$650 Million 05/18/2018 Health & Life Sciences Complete
Lead Bankers: Shawn Fitz, Stuart Irby
Public Companies
Show Tombstone

Transaction Details

  • On May 18, 2018, Ligand Pharmaceuticals Inc. (Nasdaq: LGND) announced the pricing of a private offering of $650 million aggregate principal amount of 0.75% convertible senior notes due 2023 (the “Notes”)
  • The Notes were offered in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended
  • The Notes will bear interest at a rate of 0.75%, payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2018
  • The initial conversion rate for the Notes is 4.0244 shares of LGND common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $248.48 per share of common stock)
  • The initial conversion price of the Notes represents a premium of approximately 30% to the $191.14 per share closing price of Ligand’s common stock on May 17, 2018
  • Ligand intends to use net proceeds to pay the cost of convertible note hedge transactions, to repurchase approximately $50 million of shares of LGND common stock from purchasers of the Notes in privately negotiated transactions, and for general corporate purposes, including future acquisitions and research and development
  • Stephens Inc. served as Co-Manager for the offering

About the company

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. We have a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb® is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly.

Sources: Transaction press release.
  1. This material has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets or developments referred to in the material. Information included in the material was obtained from external sources which we consider reliable, but we have not independently verified such information and do not guarantee that it is accurate or complete. Such information is believed to be accurate on the date of issuance of the material. No subsequent publication or distribution of this material shall mean or imply that any such information or opinion remains current at any time after the stated date of the material. We do not undertake to advise you of any changes in any such information or opinion. Additional information is available upon request.